Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer

View Full Paper

Ask AI

Bookmark

Neoadjuvant therapy improves resectability and survival in borderline resectable pancreatic cancer, with treatments like gemcitabine and chemotherapy.
Significant findings include the enhanced impact of neoadjuvant therapy on R0 resection rates for borderline resectable cases.
This review assesses treatment strategies and guidelines for managing pancreatic cancer using neoadjuvant approaches.
Findings suggest a need for clearer guidelines due to risks like disease progression during neoadjuvant therapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Review outlines neoadjuvant therapy's impact on surgical resection and survival in pancreatic cancer, suggesting improved outcomes.

Groszewska et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark